`Case 1:24-cv-00053-TSK Document 20-7 Filed 07/03/24 Page 1of 2 PagelD #: 2775
`
`EXHIBIT 7
`EXHIBIT 7
`
`
`
`Case 1:24-cv-00053-TSK Document 20-7 Filed 07/03/24 Page 2 of 2 PageID #: 2776
`
`From:
`To:
`Cc:
`Subject:
`Date:
`Attachments:
`
`Trask, Andrew
`MGB-Amgen-ABP938; ABP938; Ashley Hardesty Odell; Kaitlyn McKitrick
`Eylea; Eylea.Biosimilars@weil.com; REGENERONPATENT@lists.kellogghansen.com; Steve Ruby; David Pogue
`Regeneron v. Amgen, 1:24-cv-00039-TSK-JPM (N.D.W. Va.)
`Thursday, June 27, 2024 7:35:43 PM
`Formycon proposed redactions 2024-06-21 D241 SEALED Order Granting Mot for Prelim Inj against
`Formycon Redactions Applied.pdf
`
`Counsel for Amgen,
`
`The Court recently issued a decision granting Regeneron’s preliminary injunction motion against
`Formycon. Regeneron and Formycon have not yet agreed on a version of the decision that redacts
`all confidential information. Formycon, however, has provided Regeneron with a copy of the
`decision that redacts information that Formycon contends is confidential, and Formycon consented
`today to Regeneron’s production of this version of the decision to Amgen. Regeneron therefore
`provides this version of the decision as an attachment to this email. Please note that this version of
`the decision contains unredacted Regeneron confidential information, and therefore it should be
`treated as Confidential under the Protective Order governing this litigation.
`
`Best,
`Andrew
`
`Andrew Trask | Williams & Connolly LLP | 202-434-5023 | atrask@wc.com
`
`
`This message and any attachments are intended only for the addressee and may contain information that is
`privileged and confidential. If you have received this message in error, please do not read, use, copy, distribute, or
`disclose the contents of the message and any attachments. Instead, please delete the message and any attachments
`and notify the sender immediately. Thank you.
`
`